Steven M. Paul M.D.
Net Worth
Last updated:
What is Steven M. Paul M.D. net worth?
The estimated net worth of Dr. Steven M. Paul M.D. is at least $8,710,423 as of 18 Aug 2021. He owns shares worth $3,088,123 as insider and has received compensation worth at least $5,622,300 in Karuna Therapeutics, Inc. and Voyager Therapeutics, Inc..
What is the salary of Steven M. Paul M.D.?
Dr. Steven M. Paul M.D. salary is $871,050 per year as Chief Executive Officer, Pres & Chairman in Karuna Therapeutics, Inc.. He also receives $44,000 as Executive Science Advisor & Director in Voyager Therapeutics, Inc..
How old is Steven M. Paul M.D.?
Dr. Steven M. Paul M.D. is 74 years old, born in 1951.
What stocks does Steven M. Paul M.D. currently own?
As insider, Dr. Steven M. Paul M.D. owns shares in 2 companies:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Voyager Therapeutics, Inc. (VYGR) | Executive Science Advisor & Director | 872,351 | $3.54 | $3,088,123 |
| Karuna Therapeutics, Inc. (KRTX) | Chief Executive Officer, Pres & Chairman | 108,849 | $0 | $0 |
What does Voyager Therapeutics, Inc. do?
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
What does Karuna Therapeutics, Inc. do?
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of dementia-related psychosis. The company also focuses on developing other muscarinic-targeted drug candidates. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.
Steven M. Paul M.D. insider trading
Karuna Therapeutics, Inc.
Dr. Steven M. Paul M.D. has made only one insider trade between 2019-2021, according to the Form 4 filled with the SEC. He purchased 1,181 units of KRTX stock worth $125,304 on 18 Aug 2021.
As of 18 Aug 2021 he still owns at least 108,849 units of KRTX stock.
Karuna Therapeutics key executives
Karuna Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. Andrew Craig Miller (43) Co-Founder & Chief Operating Officer
- Dr. Stephen K. Brannan (69) Chief Medical Officer
- Dr. Steven M. Paul M.D. (74) Chief Executive Officer, Pres & Chairman
- Dr. Troy A. Ignelzi (57) Chief Financial Officer & Sec.